Differential modulation of lipopolysaccharide-induced expression of inflammatory genes in equine monocytes through activation of adenosine A2A receptors.

The research studied the effect of an adenosine receptor agonist, ATL313, on the expression of certain inflammatory genes in equine monocytes. The findings suggest that activation of adenosine A(2A) receptors can modulate the transcription of several pro-inflammatory mediators and has a synergistic effect on inducing anti-inflammatory actions, leading to the potential reduction of early pro-inflammatory effects in horses affected by endotoxemia.

Objective of the Study

• This research aimed to explore the impact of ATL313, an agonist for the adenosine A(2A) receptor, on the gene expression for specific pro-inflammatory and anti-inflammatory mediators in equine monocytes, targeting inflammation induced by lipopolysaccharides (LPS).

Methodology

• The researchers examined the alteration in mRNA expression of four pro-inflammatory mediators (IL-1beta, IL-8, COX-2, and TNF-alpha) and the anti-inflammatory cytokine IL-10 in LPS-treated equine cells by using ATL313.
• In addition to ATL313, the experiments also involved the use of the selective adenosine A(2A) antagonist ZM241385 and the cAMP analogue dibutyryl cAMP to study their effects.
• The P38 MAPK inhibitor, SB203580, was used as a control to compare the differential gene modulation effects of ATL313.

Findings

• ATL313 significantly reduced the LPS-induced expression of COX-2 and TNF-alpha. At the same time, it heightened the expression of IL-10 and IL-8, but there was no change in IL-1beta expression.
• The effects of ATL313 were reversed when co-incubated with the selective adenosine A(2A) antagonist ZM241385 and showed similar behavior to the cAMP analogue dibutyryl cAMP.
• Comparatively, the P38 MAPK inhibitor (SB203580) almost entirely suppressed all LPS-induced changes in mRNA expression, including TNF-alpha protein production.

Conclusion

• The study concludes that adenosine A(2A) receptor activation selectively modulates the gene expressions of certain pro-inflammatory mediators. It also enhances at least one anti-inflammatory cytokine, suggesting that selective adenosine A(2A) agonists could potentially reduce initial pro-inflammatory effects in horses struggling with endotoxemia.